Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 6,430.00
-170.00 (-2.58%)
At close: May 20, 2026
Genome & Company Revenue
In the year 2025, Genome & Company had annual revenue of 24.59B KRW, down -11.38%. Genome & Company had revenue of 5.87B in the quarter ending December 31, 2025, a decrease of -18.89%.
Revenue
24.59B
Revenue Growth
-11.38%
P/S Ratio
7.65
Revenue / Employee
n/a
Employees
n/a
Market Cap
188.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.59B | -3.16B | -11.38% |
| Dec 31, 2024 | 27.74B | 13.45B | 94.07% |
| Dec 31, 2023 | 14.30B | 211.39M | 1.50% |
| Dec 31, 2022 | 14.08B | 13.63B | 3,021.27% |
| Dec 31, 2021 | 451.25M | 300.66M | 199.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daewon Sanup | 1.06T |
| Namuga | 459.88B |
| Korea Alcohol Industrial | 423.88B |
| DAEA TI | 153.19B |
| SAMG Entertainment | 141.25B |
| Interojo | 118.44B |
| Asia Pacific Satellite | 47.81B |
| Unison | 40.27B |